Open-Label Single Arm Phase 2 Study Evaluating Dasatinib Therapy Discontinuation In Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML) With Stable Complete Molecular Response (CMR) DASFREE

Trial Profile

Open-Label Single Arm Phase 2 Study Evaluating Dasatinib Therapy Discontinuation In Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML) With Stable Complete Molecular Response (CMR) DASFREE

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Mar 2018

At a glance

  • Drugs Dasatinib (Primary)
  • Indications Chronic myeloid leukaemia
  • Focus Therapeutic Use
  • Acronyms DASFREE
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 12 Dec 2017 Results (n=84) assessing efficacy of dasatinib discontinuation in patients with chronic phase chronic myeloid leukaemia with stable complete molecular response (CMR), were presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
    • 11 Oct 2017 Planned End Date changed from 30 Nov 2021 to 10 Oct 2021.
    • 07 Aug 2017 Planned End Date changed from 1 Nov 2021 to 30 Nov 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top